Company / Depreciation & Amortization
GT Biopharma, Inc. Depreciation & Amortization History
FY2015-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$4.0K
FY2020
5-year range
$0 / $4.0K
FY2016-FY2020
Trend
+300.0%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Depreciation & Amortization changed +300% YoY in FY2020, a notable deviation from the 2-year average annual change of +125%.
Based on SEC 10-K filings.
$4,000 in FY2020 with a 3-year CAGR of +58.7%.
Increased from $2,000 to $4,000 over the past 4 years.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +58.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +58.7%, indicating consistent growth.
- In FY2020, depreciation & amortization increased 300.0% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | $4.0K | +300.0% |
| FY2017 | $1.0K | -50.0% |
| FY2016 | $2.0K | - |
| FY2015 | $0 | - |
| FY2014 | - | - |
| FY2013 | - | - |
| FY2012 | - | - |
| FY2011 | - | - |
As of FY2020 · SEC 10-K · Updated Jun 24, 2026